NCT07484022 2026-03-19Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial CancerGenerate BiomedicinesPhase 1 Not yet recruiting37 enrolled
NCT07421700 2026-02-19A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerPfizerPhase 1/2 Not yet recruiting132 enrolled